KUYDIRGI KASALLIGIDA PASSIV IMMUNOTERAPIYA: ZAMONAVIY YONDASHUVLAR VA GIPERIMMUN POLIKLONAL ZARDOBLARNING ISTIQBOLLARI

##plugins.themes.bootstrap3.article.sidebar##

PDF (Русский)
Nashr: Jild 4 Nomeri 35 : Наука и технология в современном мире
Bo'lim: Maqolalar
##semicolon##

##plugins.themes.bootstrap3.article.main##

Toshkent vaksina va zardoblar ilmiy-tadqiqot indtituti
burxanovanargiza1@gmail.com
Toshkent vaksina va zardoblar ilmiy-tadqiqot indtituti
burxanovanargiza1@gmail.com
Toshkent vaksina va zardoblar ilmiy-tadqiqot indtituti
burxanovanargiza1@gmail.com

Abstrak:

Kuydirgi (Bacillus anthracis) yuqori o‘lim ko‘rsatkichiga ega bo‘lgan, biologik xavfli infeksion kasalliklardan biri hisoblanadi. Kasallikni davolashda antibiotiklar asosiy o‘rin tutishiga qaramay, bakteriyaning vegetativ shakli tomonidan ishlab chiqariladigan letal va shish toksinlari mikroorganizmlar yo‘q qilingandan so‘ng ham patogenezni davom ettiradi. Shu sababli toksinlarni neytrallashga qaratilgan passiv immunoterapiya kuydirgini davolash va oldini olishda muhim qo‘shimcha strategiya sifatida qaralmoqda. Ushbu ishda kuydirgida qo‘llanilayotgan zamonaviy passiv immunoterapiya vositalari, xususan monoklonal antitanalar va inson plazmasidan olingan immunoglobulinlar tahlil qilindi. Shuningdek, tarixiy va zamonaviy ma’lumotlar asosida ot asosida olingan giperimmun poliklonal zardobning samaradorligi, iqtisodiy va texnologik afzalliklari baholandi.

##plugins.themes.bootstrap3.article.details##

##submission.howToCite##:

Burxanova , N., Ashurov , A., & Sa’dinov , P. (2025). KUYDIRGI KASALLIGIDA PASSIV IMMUNOTERAPIYA: ZAMONAVIY YONDASHUVLAR VA GIPERIMMUN POLIKLONAL ZARDOBLARNING ISTIQBOLLARI. Наука и технология в современном мире, 4(35), 91–92. Retrieved from https://in-academy.uz/index.php/zdift/article/view/69707

##submission.citations##:

FDA. Approval letter for post-exposure prophylaxis in pediatric patients ( levofloxacin). Rockville, MD: FDA; 2008a. [July 23, 2011].

WHO. Humans and Animals. World Health Organization; Geneva, Switzerland: 2008. Anthrax.

FDA. Approval letter for post-exposure prophylaxis in adults (levofloxacin). Rockville, MD: FDA; 2004. [July 23, 2011].

WHO. Humans and Animals. World Health Organization; Geneva, Switzerland: 2008. Anthrax